Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $22.00 Price Target at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB - Free Report) had its price objective boosted by HC Wainwright from $21.00 to $22.00 in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other brokerages have also commented on YMAB. Canaccord Genuity Group increased their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a buy rating in a research report on Monday, March 4th. Wedbush restated an outperform rating and issued a $18.00 price target (up from $12.00) on shares of Y-mAbs Therapeutics in a research report on Monday, February 12th. Finally, BMO Capital Markets raised their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an outperform rating in a research report on Monday, March 4th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and a consensus target price of $16.57.

Y-mAbs Therapeutics Trading Down 0.7 %

Shares of Y-mAbs Therapeutics stock traded down $0.09 during mid-day trading on Monday, reaching $12.19. 543,174 shares of the stock were exchanged, compared to its average volume of 408,067. The company has a market cap of $534.90 million, a price-to-earnings ratio of -24.88 and a beta of 0.78. Y-mAbs Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $20.90. The firm has a 50-day simple moving average of $15.48 and a 200 day simple moving average of $11.29.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.17. The business had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. On average, research analysts predict that Y-mAbs Therapeutics will post -0.48 EPS for the current fiscal year.

Insider Transactions at Y-mAbs Therapeutics

In other news, SVP Vignesh Rajah sold 1,711 shares of the business's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 21.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Trexquant Investment LP grew its stake in shares of Y-mAbs Therapeutics by 417.5% in the third quarter. Trexquant Investment LP now owns 76,585 shares of the company's stock worth $417,000 after purchasing an additional 61,785 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Y-mAbs Therapeutics by 24.0% in the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company's stock worth $4,420,000 after acquiring an additional 157,173 shares during the last quarter. GSA Capital Partners LLP raised its holdings in shares of Y-mAbs Therapeutics by 208.3% in the 3rd quarter. GSA Capital Partners LLP now owns 137,299 shares of the company's stock worth $748,000 after acquiring an additional 92,765 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Y-mAbs Therapeutics in the 4th quarter valued at about $34,000. Finally, Massachusetts Financial Services Co. MA increased its stake in Y-mAbs Therapeutics by 258.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company's stock valued at $448,000 after buying an additional 59,201 shares during the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.